| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PLRX | Common Stock | Award | $0 | +75.6K | +16.96% | $0.00 | 522K | Jul 9, 2024 | Direct | F1, F2 |
| holding | PLRX | Common Stock | 409K | Jul 9, 2024 | See footnote | F3 |
| Id | Content |
|---|---|
| F1 | On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 75,625 shares. |
| F2 | Includes 1,489 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. |
| F3 | Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |